首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Randomized Clinical Trial: The Clinical Effects of Herb-Partitioned Moxibustion in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome
【24h】

Randomized Clinical Trial: The Clinical Effects of Herb-Partitioned Moxibustion in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome

机译:随机临床试验:草药分区灸治疗腹泻型肠易激综合征的临床效果

获取原文
       

摘要

Objective. To explore the efficacy of Herb-partitioned moxibustion in treating IBS-D patients.Method. 210 IBS-D patients were randomly assigned on a3:3:2basis to group HM, group FM, or group PB for 4-week treatment. The change of GSRS total score at weeks 4 and 8, the changes of GSRS specific scores, and adverse events were evaluated.Results. Patients in group HM and group FM had lower GSRS total score at week 4 (1.98±0.303,2.93±0.302versus3.73±0.449) and at week 8 (2.75±0.306,3.56±0.329versus4.39±2.48) as compared with patients’ score in group PB. However, there was no significant difference of GSRS total score between group HM and group FM. The effect of HM was significantly greater than that of orally taking PB in ameliorating the symptoms of rugitus (0.38 versus 0.59,P<0.05), abdominal pain (0.28 versus 0.57,P<0.01), abdominal distension (0.4 versus 0.7,P<0.01), and increased passage of stools (0.06 versus 0.25,P<0.01) at the end of treatment period. In the follow-up period, patients’ therapeutic effect in group HM remained greater than that in group FM (in abdominal pain, abdominal distension, and increased passage of stools) and that in group PB (in loose stools).Conclusions. HM appears to be a promising, efficacious, and well-tolerated treatment for patients with IBS-D.
机译:目的。探讨中草药分区灸法治疗IBS-D的疗效。将210名IBS-D患者按3:3:2的基础随机分配到HM组,FM组或PB组,进行4周治疗。评估第4周和第8周GSRS总分的变化,GSRS具体分数的变化以及不良事件。 HM组和FM组的患者在第4周(1.98±0.303,2.93±0.302对3.37±0.449)和第8周(2.75±0.306,3.56±0.329对4.39±2.48)的GSRS总评分较低PB组患者得分。但是,HM组和FM组之间的GSRS总分没有显着差异。 HM的效果明显优于口服PB来改善皱纹症状(0.38 vs 0.59,P <0.05),腹痛(0.28 vs 0.57,P <0.01),腹胀(0.4 vs 0.7,P <0.01) 0.01),并在治疗期结束时增加了粪便通过率(0.06对0.25,P <0.01)。在随访期间,HM组的患者的疗效仍高于FM组(在腹痛,腹胀和大便通畅方面)和PB组(在稀便中)的疗效。对于IBS-D患者,HM似乎是一种有前途,有效且耐受性良好的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号